Pfizer Biontech
-
{
- All
- News
- Videos
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
"Fill And Finish": Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa
Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.
-
Pfizer, BioNTech Seeks Full US Approval For Covid Vaccine
Pfizer and BioNTech said Friday they were launching an application requesting full US regulatory approval for their game-changing Covid-19 vaccine for individuals 16 years and older.
-
Pfizer And BioNTech Seek Covid Vaccine Approval For 12-15-Year Olds In EU
Pfizer/BioNTech said Friday they have asked European regulators to authorise their Covid-19 vaccine for 12 to 15-year-old, following a similar move in the United States earlier this month.
-
BioNTech Eyes Covid Vaccine For 12-15 Year Olds From June In Europe
BioNTech said Thursday that it expected its Covid-19 vaccine, jointly developed with Pfizer, to be available to 12 to 15-year-olds in Europe from June.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
The Pfizer/BioNTech Vaccine Bet That Paid Off
With a strategic alliance, 24-hour production and a bit of luck, Pfizer and BioNTech were able to roll out their Covid vaccine at a brisk pace and relatively free of controversy.
-
Pfizer Says Its Coronavirus Vaccine Can Be Stored In Ordinary Freezers
Germany's BioNTech and its US partner Pfizer on Friday said tests have shown that their coronavirus vaccine can stand warmer temperatures than initially thought, potentially simplifying the jab's complex cold-chain logistics.
-
WHO Europe Urges "Safe Compromise" On Timing Of Covid Vaccine Doses
European countries rolling out the Pfizer-BioNTech COVID-19 vaccine should be flexible on the time between the first and second doses, the World Health Organization's director for the region said on Thursday.
-
WHO Recommends 2 Doses Of Pfizer Covid Vaccine Within 21-28 Days
COVID-19 patients should take two doses of the new Pfizer/BioNTech vaccine within a period of 21-28 days, the head of the World Health Organization's immunization advisory group said on Tuesday.
-
Pfizer-BioNTech To Test Combined Vaccine For Covid, Flu
Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.
-
US Is Considering Second Covid Booster For 65+
Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Three Doses "Effective" Against Omicron: Pfizer/BioNTech
Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
"Fill And Finish": Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa
Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.
-
Pfizer, BioNTech Seeks Full US Approval For Covid Vaccine
Pfizer and BioNTech said Friday they were launching an application requesting full US regulatory approval for their game-changing Covid-19 vaccine for individuals 16 years and older.
-
Pfizer And BioNTech Seek Covid Vaccine Approval For 12-15-Year Olds In EU
Pfizer/BioNTech said Friday they have asked European regulators to authorise their Covid-19 vaccine for 12 to 15-year-old, following a similar move in the United States earlier this month.
-
BioNTech Eyes Covid Vaccine For 12-15 Year Olds From June In Europe
BioNTech said Thursday that it expected its Covid-19 vaccine, jointly developed with Pfizer, to be available to 12 to 15-year-olds in Europe from June.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
The Pfizer/BioNTech Vaccine Bet That Paid Off
With a strategic alliance, 24-hour production and a bit of luck, Pfizer and BioNTech were able to roll out their Covid vaccine at a brisk pace and relatively free of controversy.
-
Pfizer Says Its Coronavirus Vaccine Can Be Stored In Ordinary Freezers
Germany's BioNTech and its US partner Pfizer on Friday said tests have shown that their coronavirus vaccine can stand warmer temperatures than initially thought, potentially simplifying the jab's complex cold-chain logistics.
-
WHO Europe Urges "Safe Compromise" On Timing Of Covid Vaccine Doses
European countries rolling out the Pfizer-BioNTech COVID-19 vaccine should be flexible on the time between the first and second doses, the World Health Organization's director for the region said on Thursday.
-
WHO Recommends 2 Doses Of Pfizer Covid Vaccine Within 21-28 Days
COVID-19 patients should take two doses of the new Pfizer/BioNTech vaccine within a period of 21-28 days, the head of the World Health Organization's immunization advisory group said on Tuesday.
